Literature DB >> 13981319

A phase I study of hydroxyurea.

W G THURMAN, C BLOEDOW, C D HOWE, W C LEVIN, P DAVIS, M LANE, M P SULLIVAN, K M GRIFFITH.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; UREA

Mesh：

Substances：

Year:  1963        PMID： 13981319

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  7 in total

Review 1.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  [Studies on the teratogenic effect of hydroxyurea during the early and embryonic development of mice].

Authors:  R Roll; F Bär
Journal:  Arch Toxikol       Date:  1969

3.  [Studies on synchronisation in vivo: temporary inhibition of DNA synthesis in normal and malignant mammalian cell systems with hydroxyurea].

Authors:  M F Rajewsky; D F Hülser; E Fabricius
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1971

4.  [Cytokinetic studies on the proliferating activity of mast cells in the regnerating bone marrow of the rat].

Authors:  R J Haas; I Fache
Journal:  Blut       Date:  1973-03

5.  Phase 1 study of high-dose hydroxyurea in lung cancer.

Authors:  D Veale; B M Cantwell; N Kerr; A Upfold; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.